Research progress on the transition from acute kidney injury to chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2024.02.009

Abstract

Abstract:

Although some patients with acute kidney injury (AKI) got clinical recovery, they still experienced renal tissue fibrosis due to changes in renal structure and maladaptive repair, leading to progression to chronic kidney disease (CKD) and even end-stage renal disease (ESRD). Therefore, early identification and intervention of the AKI-to-CKD transition is crucial. This article reviewed the research progress on the risk factors, transition mechanisms, biomarkers, and intervention measures of the AKI-to-CKD transition.

Key words: Acute kidney injury, Chronic kidney disease, Transition, Mechanisms, Biomarkers, Intervention

Yinan Zhang, Guozhen Zhu. Research progress on the transition from acute kidney injury to chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 106-112.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2024.02.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2024/V13/I02/106

Figures/Tables 2

References 45

[1]	Kung CW, Chou YH. Acute kidney disease: an overview of the epidemiology, pathophysiology, and management [J]. Kidney Res Clin Pract, 2023, Epub ahead of print.
[2]	Guzzi F, Cirillo L, Roperto RM, et al. Molecular mechanisms of the acute kidney injury to chronic kidney disease transition: an updated view [J]. Int J Mol Sci, 2019, 20(19): 4941.
[3]	Thakar CV, Christianson A, Himmelfarb J, et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus [J]. Clin J Am Soc Nephrol, 2011, 6(11): 2567-2572.
[4]	Kurzhagen JT, Dellepiane S, Cantaluppi V, et al. AKI: an increasingly recognized risk factor for CKD development and progression [J]. J Nephrol, 2020, 33(6): 1171-1187.
[5]	Saranya GR, Viswanathan P. Gut microbiota dysbiosis in AKI to CKD transition [J]. Biomed Pharmacother, 2023, 161: 114447.
[6]	Chen JY, Tsai I, Pan HC, et al. The impact of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on clinical outcomes of acute kidney disease patients: a systematic review and meta-analysis [J]. Front Pharmacol, 2021, 12: 665250.
[7]	Ciarambino T, Crispino P, Giordano M. Gender and renal insufficiency: opportunities for their therapeutic management? [J]. Cells, 2022, 11(23): 3820.
[8]	Wang Z, Zhang C. From AKI to CKD: maladaptive repair and the underlying mechanisms [J]. Int J Mol Sci, 2022, 23(18): 10880.
[9]	McWilliam SJ, Wright RD, Welsh GI, et al. The complex interplay between kidney injury and inflammation [J]. Clin Kidney J, 2021, 14(3): 780-788.
[10]	Tinti F, Lai S, Noce A, et al. Chronic kidney disease as a systemic inflammatory syndrome: update on mechanisms involved and potential treatment [J]. Life (Basel), 2021, 11(5): 419.
[11]	Wu YS, Liang S, Li DY, et al. Cell cycle dysregulation and renal fibrosis [J]. Front Cell Dev Biol, 2021, 9: 714320.
[12]	Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury [J]. Nat Med, 2010, 16(5): 535-543.
[13]	Zhang X, Agborbesong E, Li X. The role of mitochondria in acute kidney injury and chronic kidney disease and its therapeutic potential [J]. Int J Mol Sci, 2021, 22(20): 11253.
[14]	Bartoszewska S, Collawn JF. Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia [J]. Cell Mol Biol Lett, 2020, 25: 18.
[15]	Chen F, Gao Q, Wei A, et al. Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis [J]. Cell Death Differ, 2021, 28(3): 1001-1012.
[16]	Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, et al. Targeting epigenetic DNA and histone modifications to treat kidney disease [J]. Nephrol Dial Transplant, 2018, 33(11): 1875-1886.
[17]	Zhou Q, Chen W, Yu XQ. Long non-coding RNAs as novel diagnostic and therapeutic targets in kidney disease [J]. Chronic Dis Transl Med, 2020, 5(4): 252-257.
[18]	Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression [J]. J Am Soc Nephrol, 2015, 26(8): 1765-1776.
[19]	Zhu Z, Hu J, Chen Z, et al. Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming [J]. Metabolism, 2022, 131: 155194.
[20]	Baudoux T, Jadot I, Declèves AE, et al. Experimental aristolochic acid nephropathy: a relevant model to study AKI-to-CKD transition [J]. Front Med (Lausanne), 2022, 9: 822870.
[21]	Aggarwal D, Singh G. Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats [J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(4): 615-627.
[22]	Ciarambino T, Crispino P, Giordano M. Gender and renal insufficiency: opportunities for their therapeutic management? [J]. Cells, 2022, 11(23): 3820.
[23]	McCoy IE, Hsu JY, Bonventre JV, et al. Acute kidney injury associates with long-term increases in plasma TNFR1, TNFR2, and KIM-1: findings from the CRIC study [J]. J Am Soc Nephrol, 2022, 33(6): 1173-1181.
[24]	Tuan PNH, Quyen DBQ, Van Khoa H, et al. Serum and urine neutrophil gelatinase-associated lipocalin levels measured at admission predict progression to chronic kidney disease in sepsis-associated acute kidney injury patients [J]. Dis Markers, 2020, 2020: 8883404.
[25]	Cooper DS, Claes D, Goldstein SL, et al. Follow-up renal assessment of injury long-term after acute kidney injury (FRAIL-AKI) [J]. Clin J Am Soc Nephrol, 2016, 11(1): 21-29.
[26]	Ichikawa D, Kamijo-Ikemori A, Sugaya T, et al. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion [J]. Nephrology (Carlton), 2018, 23(4): 308-316.
[27]	Cho WY, Lim SY, Yang JH, et al. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury [J]. Korean J Intern Med, 2020, 35(3): 662-671.
[28]	Zheng Z, Xu K, Li C, et al. NLRP3 associated with chronic kidney disease progression after ischemia/reperfusion-induced acute kidney injury [J]. Cell Death Discov, 2021, 7(1): 324.
[29]	Xing Z, Gong K, Hu N, et al. The reduction of uromodulin, complement factor H, and their interaction is associated with acute kidney injury to chronic kidney disease transition in a four-time cisplatin-injected rat model [J]. Int J Mol Sci, 2023, 24(7): 6636.
[30]	Menez S, Moledina DG, Garg AX, et al. Results from the TRIBE-AKI study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery [J]. Kidney Int, 2021, 99(3): 716-724.
[31]	Liu Z, Tan RJ, Liu Y. The many faces of matrix metalloproteinase-7 in kidney diseases [J]. Biomolecules, 2020, 10(6): 960.
[32]	Yin J, Wang F, Kong Y, et al. Antithrombin III prevents progression of chronic kidney disease following experimental ischaemic-reperfusion injury [J]. J Cell Mol Med, 2017, 21(12): 3506-3514.
[33]	Zhao JY, Wu YB. Huaier extract attenuates acute kidney injury to chronic kidney disease transition by inhibiting endoplasmic reticulum stress and apoptosis via miR-1271 upregulation [J]. Biomed Res Int, 2020, 2020: 9029868.
[34]	Wu M, Chen W, Miao M, et al. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability [J]. Clin Sci (Lond), 2021, 135(14): 1707-1726.
[35]	Nishida K, Watanabe H, Murata R, et al. Recombinant long-acting thioredoxin ameliorates AKI to CKD transition via modulating renal oxidative stress and inflammation [J]. Int J Mol Sci, 2021, 22(11): 5600.
[36]	Chen DQ, Cao G, Zhao H, et al. Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum [J]. Ther Adv Chronic Dis, 2019, 10: 2040622319869116.
[37]	Abdelmageed MM, Kefaloyianni E, Arthanarisami A, et al. TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment [J]. Nephrol Dial Transplant, 2023, 38(5): 1139-1150.
[38]	Zahan MS, Ahmed KA, Moni A, et al. Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances [J]. Korean J Physiol Pharmacol, 2022, 26(1): 1-13.
[39]	Jia Y, Kang X, Tan L, et al. Nicotinamide mononucleotide attenuates renal interstitial fibrosis after AKI by suppressing tubular DNA damage and senescence [J]. Front Physiol, 2021, 12: 649547.
[40]	Lok SWY, Yiu WH, Li H, et al. The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis [J]. Clin Sci (Lond), 2020, 134(21): 2873-2891.
[41]	Yu Y, Chen M, Guo Q, et al. Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage [J]. Cell Mol Biol Lett, 2023, 28(1): 12.
[42]	Mapuskar KA, Vasquez-Martinez G, Mayoral-Andrade G, et al. Mitochondrial oxidative metabolism: an emerging therapeutic target to improve CKD outcomes [J]. Biomedicines, 2023, 11(6): 1573.
[43]	Li C, Shen Y, Huang L, et al. Senolytic therapy ameliorates renal fibrosis postacute kidney injury by alleviating renal senescence [J]. FASEB J, 2021, 35(1): e21229.
[44]	Li J, Gong X. Tetramethylpyrazine: an active ingredient of Chinese herbal medicine with therapeutic potential in acute kidney injury and renal fibrosis [J]. Front Pharmacol, 2022, 13: 820071.
[45]	Kurata Y, Nangaku M. Use of antibiotics as a therapeutic approach to prevent AKI-to-CKD progression [J]. Kidney Int, 2023, 104(3): 418-420.

Please choose a citation manager

Content to export